Fig. 1 (IMAGE)
Caption
Targeting cardiomyocyte steatosis cures heart failure:
Heart failure is a pandemic in the aging population. Targeting myocardial long-chain triglyceride in lipid droplets by another triglyceride, tricaprin, could sustain and recover patients’ hearts, which is a practical SDG for human health.
A woman in her 50s started tricaprin after five hospitalisations for progressive heart failure during the prior 18 months, even receiving multiple drugs for HF. She had a medical history of progressive chronic kidney disease for 3 years, which eventually required haemodialysis. Her cardiac function completely recovered, along with reverse left ventricular remodelling and was maintained for over 7 years after the initiation of tricaprin.
Credit
2025 Hirano et al., Long-term survival and durable recover of heart failure in patients with triglyceride deposit cardiomyovasculopathy treated with tricaprin. Nature Cardiovascular Research
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted.
License
CC BY-NC